Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cofetuzumab Pelidotin in PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
NCT04189614Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Feb 2020
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of cofetuzumab pelidotin in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc. Primary endpoint: Objective Response Rate. Started Feb 2020; status: terminated.
02
Drugs
cofetuzumab pelidotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04189614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189614.